1) Stokes AH, Hastings TG, Vrana KE:Cytotoxic and genotoxic potential to dopamine. J Neurosci Res 55:659-665, 1999
2) 水野美邦,近藤智善:よくわかるパーキンソン病のすべて.パーキンソン病の原因(望月秀樹編),永井書店,pp277-296,2004
3) Berman SB, Zigmond MJ, Hastings TG, et al:Modification of dopamine transporter function. J Neurochem 67:593-600, 1996
4) Xu Y, Stokes AH, Roskoski R Jr, et al:Dopamine, in the presence of tyrosinase, covalently modifies and inactivates tyrosine hydroxylase. J Neurosci Res 54:691-697, 1998
5) Jenner P:Oxidative stress in Parkinson's disease. Ann Neurol 53 (Suppl 3):S26-38, 2003
6) Przedborski S, Kostic V, Jackson-Lewis V, et al:Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity. J Neurosci 12:1658-1667, 1992
7) Zhang J, Graham DG, Montine TJ, et al:Enhanced N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity in mice deficient in CuZn-superoxide dismutase or glutathione peroxidase. J Neuropathol Exp Neurol 59:53-61, 2000
8) Betarbet R, Sherer TB, MackKenzie G, et al:Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Med 3:1301-1306, 2004
9) Conway KA, Rochet JC, bieganski RM:Kinetic stabilization of the α-synuclein protofibril by a dopamine-α-synuclein adduct. Science 294:1346-1349, 2001
10) Shimura H, Hattori N, Kubo S, et al:Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet 25:302-305, 2000
11) Shamoto-Nagai N, Maruyama W, Isobe K, et al:An inhibitor of mitochondrial complex 1, rotenone, inactivates proteasome by oxidative modification and induces aggregation of oxidized proteins in SH-SY5Y cells. J Neurosci Res 74:589-597, 2003
12) 有賀寛芳:DJ-1と神経細胞死.医学のあゆみ 208:493-497, 2004
13) Shendelman S, Jonason A, Martinat C, et al:DJ-1 is a redox-dependent molecular chaperone that inhibits α-synuclein aggregate formation. PLoS Biol 2:1764-1773, 2004
14) Bandopadhyay R, Kingsbury AE, Cookson MR, et al:The expression of DJ-1 (PARK7) in normal human CNS and idiopathic Parkinson's disease. Brain 127:420-430, 2004
15) Stocchi F, Olanow CW:Neuroprotection in Parkinson's disease;clinical trials. Ann Neurol 53 (Supple 3):S87-97, 2003